Copy
CANCER CLINICAL TRIALS NEWSLETTER

This is a multi center, Phase 1 study consisting of 2 parts. The first part of the study is evaluating the safety and tolerability of NGM120. The second part of the study is studying safety and tolerability of NGM120 in combination with gemcitabine and Abraxane, as well as obtain evidence of antitumor activity and anti-CACS activity in the management of metastatic pancreatic cancer. In a BxPC3 pancreatic cancer model, tumors regressed upon the treatment with gemcitabine and Abraxane, and the regrowth significantly delayed when NGM120 was used concurrently with this chemotherapy regimen. In addition, NGM120 enhanced antitumor activity of anti-PD-1 antibodies in a study done on mice. 

(NGM18-0402, IRB 2019-0836)

QED Therapeutics
QBGJ398-301
IRB 2019-0732
A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: the PROOF Trial
NRG-LU005
IRB 2019-0826
LIMITED STAGE SMALL CELL LUNG CANCER (LS-SCLC): A PHASE II/III RANDOMIZED STUDY OF CHEMORADIATION VERSUS
CHEMORADIATION PLUS ATEZOLIZUMAB

 
Click Here to Download All Cancer Trials Open to Accrual
Questions?  Please call us at 513-584-7698, or email us!
UC researcher hopes to use electricity to improve brain cancer treatment

UC researchers are currently studying a method to improve the treatment for Glioblastoma Multiforme, using electricity to make GBM Cancer cells more receptive to medication. 
Click Here to Visit the UC Newsroom
MULTIDISCIPLINARY MANAGEMENT
OF GASTROINTESTINAL CANCERS


Saturday, Oct. 12, 2019  | 7:30 a.m.–12:00 p.m.
The Manor House Banquet & Conference Center
7440 S. Mason-Montgomery Road
Mason, Ohio 45040

Keynote Speaker:
E. Gabriela Chiorean, MD
Professor of Medicine; Director of GI Oncology
University of Washington / Fred Hutchinson Cancer Research Center


For more information or questions, email kelly.hummel@uc.edu, or call 513-558-2030.

View Flyer as PDF
Division of Hematology Oncology Grand Rounds Schedule
Facebook
Twitter
UC Health Office of Clinical Research
Email Us
Check out our YouTube chanel!
Copyright © 2019, All rights reserved.

UC Cancer Institute Clinical Trials Office
200 Albert Sabin Way
Suite 4002A, ML 0502
Cincinnati, OH 45267-0502
513-584-7698    F 513-558-0071

Unsubscribe to this newsletter by emailing:
natalie.ciulla@uc.edu






This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
UCCI Clinical Trials · 200 Albert Sabin Way Ste 4002A · Ml 0502 · Cincinnati, OH 45267-0502 · USA